

- Canadian Infectious Disease Society**
Background, funding, etc., 15:14-5
See also Witnesses
- Canadian Labour Congress**
Legislation, Bill C-22, members' opinions soliciting, 6:58
See also Witnesses
- Canadian Medical Association**
Health care advocacy role, questioning, 14:31
See also Witnesses
- Canadian Nurses' Association** *see* National Federation of Nurses' Unions—Political affiliations
- Canadian Patent Office** *see* Consumer and Corporate Affairs Department; Drug patents
- Canadian Red Cross Society** *see* Medical Research Council—Budget
- Canadian Society for Clinical Investigation**
Background, 12:39
Eastman report views, 12:34
See also Witnesses
- Canadian Society of Clinical Pharmacology** *see* Witnesses
- Canadian Society of Industrial Pharmacists**
Background, 15:33
See also Witnesses
- Cangene Corp.**, 16:17, 58, 60-3, 65, 80; 17:50
Joint ventures, 8:39
Research, staff, etc., 8:41
See also Witnesses
- Cappe, Mel** (Consumer and Corporate Affairs Department)
Patent Act (amdt.)(Bill C-22), 1:5, 32, 38; 16:3, 7, 24-5, 29, 63-4, 69, 71, 73, 78; 17:10, 26-7, 30, 33
- Cardiovascular medicine**
Drug therapy, medical progress, 14:16-7
- Carr, Shirley**
References, New Democratic Party affiliation, 6:58
- CDC Life Sciences**, 1:34
- CDMA** *see* Canadian Drug Manufacturers Association
- Chairman, decisions and statements** *see* Procedure and Committee business
- Chapman, Dr. Ross** (National Pensioners and Senior Citizens Federation)
Patent Act (amdt.)(Bill C-22), 8:4, 59-68
References, background, 8:65-6
- Chemicals** *see* Agricultural chemicals; Fine chemicals
- Chernecki, Vera** (National Federation of Nurses' Unions)
Patent Act (amdt.)(Bill C-22), 9:3, 29, 33-4, 36-7
- China** *see* Brand name drugs—Exclusivity period from imports
- Chrétien, Michel** (L'Institut de recherches cliniques de Montréal)
Patent Act (amdt.)(Bill C-22), 10:3, 34-46
References, background, 10:45
- Ciba-Geigy Canada Ltd.**
Research and development, decentralising, speculation, 3:66
- Cimetidine** *see* Tagamet/cimetidine
- Clemenhagen, Carol** (Canadian Hospital Association)
Patent Act (amdt.)(Bill C-22), 15:3, 21, 24, 27, 29
- Coalition nationale pour la recherche en science de la santé** *see* Witnesses
- Coalition of Provincial Organizations of the Handicapped**
Background, 15:83-4
See also Witnesses
- Coalition of Scientists, University of Toronto** *see* Witnesses
- Cochrane, William** (National Biotechnology Advisory Committee)
Patent Act (amdt.)(Bill C-22), 12:3, 42-54
- Cohen, Andrew** (Consumers Association of Canada)
Patent Act (amdt.)(Bill C-22), 6:3, 18-9, 22-4, 29, 31-4
- Collins, Mary** (PC—Capilano)
Biotechnology industry, 8:48-9, 57-8; 12:52-3
Brand name drugs, 1:33; 13:29; 14:17-8
Canadian Cardiovascular Society, 14:16
Cardiovascular medicine, 14:16-7
Consumer and Corporate Affairs Department, M. (Dingwall), 13:34
Drug patents, 16:29, 31-2, 34-7, 39
Drug plans, 8:13
Drug Prices Review Board, 1:31; 6:70-1; 13:29-31
Drugs and pharmaceuticals, 1:30-3; 6:70, 86-7, 88; 14:19, 73-5
Drugs and pharmaceuticals industry, 1:33-4; 13:31; 14:73-6
Economic Council of Canada, 14:73
Generic drugs, 1:31-2; 6:69-70, 85-6; 8:14-5
Gorecki, background, 14:72
Green Shield Prepaid Services Inc., 6:87
Health care, 13:28; 14:18, 75
Multiple sclerosis, 8:13-4
Multiple Sclerosis Society of Ottawa-Carleton, 8:13
National Health and Welfare Department, M. (Dingwall), 13:34
Patent Act (amdt.)(Bill C-22), 1:30-4; 6:69-71, 85-8; 8:13-5, 30, 48-9, 57-8; 12:52-4; 13:28-31, 34; 14:16-20, 72-6, 78; 15:100; 16:29-31, 34-7, 39; 17:44-5
Procedure and Committee business
Bills, 17:44-5
Witnesses, 8:30; 14:78
Senior citizens, 14:19
Universities, 14:17
- Committee**
Members, privileges breaching, referral to House, 9:23
Witnesses
Inviting
Canadian Federation of Biological Societies, 14:5
Canadian individuals and groups, only, 8:29
Council of Canadians, 15:70
Manitoba Government, 14:5, 76-8
National Federation of Nurses' Unions, 9:30-1
Scheduling, Calenti, rescheduled, no notice, 9:10, 40
See also Patent Act (amdt.)(Bill C-22)—References, Expediting; Procedure and Committee business
- Community Health Co-operative Federation of Saskatchewan**
Drug prescribing habits, cost study, 11:66-8, 78-80
Saskatchewan government, consultation *re* Bill C-22, 11:69
Saskatchewan Prescription Drug Fund Organization, consultation *re* Bill C-22, 11:70
See also Witnesses
- Compendium of Pharmaceuticals and Specialties** *see* Drug prescriptions
- Competition** *see* Drugs and pharmaceuticals industry